<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01049776</url>
  </required_header>
  <id_info>
    <org_study_id>ILCC #2 IllinoisCancerCare #2</org_study_id>
    <nct_id>NCT01049776</nct_id>
  </id_info>
  <brief_title>GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line</brief_title>
  <official_title>A Phase II Study of GW786034 in Patients With Non Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens. An Institutional Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Illinois CancerCare, P.C.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Illinois CancerCare, P.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung Cancer is the most common cause of cancer death in the United States with an estimated&#xD;
      mortality in excess of 160,000, more than the combined mortality seen with prostate, breast,&#xD;
      colorectal cancers(1). Most patients with Lung Cancer have Non-Small Cell Lung Cancers(&#xD;
      NSCLC) and only 25-30% of patients with NSCLC (Non Small Cell Lung Cancer) have resectable&#xD;
      disease( Stage I or II) at the time of diagnosis.&#xD;
&#xD;
      The vast majority of patients with advanced NSCLC (Non Small Cell Lung Cancer) are not&#xD;
      curable and overall five year survival is 11%-14%1.&#xD;
&#xD;
      Chemotherapy is beneficial for patients with locally advanced and metastatic disease.&#xD;
      Numerous phase III studies have determined the superiority of systemic chemotherapy over best&#xD;
      supportive care. Platinum based chemotherapy has been widely accepted as the standard of care&#xD;
      for the initial treatment of advanced NSCLC.&#xD;
&#xD;
      However first line chemotherapy is modest at best. A randomized trial comparing four of the&#xD;
      most commonly used chemotherapy regimens in the United States not only failed to show a&#xD;
      clearly superior arm but also confirmed the dismal prognosis of these patients. The response&#xD;
      rate for all 1207 patients was 18.6% with a median survival of eight months and one year&#xD;
      survival of 33.5 % and a two year survival of 12%5. Clearly a different paradigm is needed&#xD;
      for the treatment of this disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Better therapies for patients with NSCLC (Non Small Cell Lung Cancer) who progress after&#xD;
      initial chemotherapy is urgently needed.&#xD;
&#xD;
      Besides VEGF (vascular endothelial growth factor), human lung cancers are known to express&#xD;
      PDGFR (platelet-derived growth factor receptors). NSCLC, like most cancers, involves defects&#xD;
      in signal transduction pathways. Receptor tyrosine kinases (RTKs) play a pivotal role in&#xD;
      these signaling pathways, transmitting extracellular molecular signals into the cytoplasm&#xD;
      and/or nucleus of a cell. Among such RTKs are the receptors for polypeptide growth factors&#xD;
      such as epidermal growth factor (EGF), insulin, platelet-derived growth factor (PDGF),&#xD;
      neurotrophins (i.e., NGF), and fibroblast growth factor (FGF). Phosphorylation of such RTKs&#xD;
      activates their cytoplasmic domain kinase function, which in turns activates downstream&#xD;
      signaling molecules. Thus, RTKs are key mediators of cellular signaling as well as&#xD;
      oncogenesis resulting from over-expression and activation of such RTKs and their substrates.&#xD;
      Due to their pivotal role in normal and aberrant signaling, RTKs are the subject of&#xD;
      increasing focus as potential drug targets for the treatment of certain types of cancer. For&#xD;
      example, Herceptin.RTM., an inhibitor of HER2/neu, is currently an approved therapy for a&#xD;
      certain subset of breast cancer. Iressa.TM. (ZD1839) and Tarceva.TM. (OSI-774), both&#xD;
      small-molecule inhibitors of EGFR, have been approved for the treatment of NSCLC.&#xD;
&#xD;
      Platelet-derived growth factor (PDGF) and its receptors (PDGFRs) are a family of RTKs that&#xD;
      play an important role in the regulation of normal cell growth and differentiation. PDGFRs&#xD;
      are involved in a variety of pathological processes, including atherosclerosis, neoplasia,&#xD;
      tissue repair, and inflammation. PDGFRs, which consist of two isoforms (alpha and beta), are&#xD;
      membrane protein-tyrosine kinases that, upon binding to PDGF, become activated and, via&#xD;
      recruitment of SH domain-containing effector molecules, initiate distinct or overlapping&#xD;
      signaling cascades that coordinate cellular responses.&#xD;
&#xD;
      Expression of a constitutively active PDGFR leads to cellular transformation and suggests&#xD;
      that, in normal cells, PDGFR activity must be tightly regulated to oppose continuous&#xD;
      activation of its downstream effectors. PDGFR beta, for example, is known to be&#xD;
      over-expressed in a large number of tumors, and PDGF treatment causes transformation and&#xD;
      malignant tumors in a variety of experimental systems. One study reported the apparent&#xD;
      expression of PDGFR alpha in nearly 100% of human lung cancer tumors examined, and reported&#xD;
      the growth inhibition of a lung cancer cell line, A549, by Gleevec, an effect that was&#xD;
      surmised to be mediated via PDGFR inhibition.&#xD;
&#xD;
      Donnem et al evaluated 335 resected patients with stage I to III with NSCLC. Using IHC&#xD;
      (immunohistochemical staining) the expression of PDGF-A, -B, -C and -D along with PDGFR alpha&#xD;
      and beta. In multivariant analysis high tumor cell expression of PDGF-B and PDGF- alpha were&#xD;
      independent negative prognostic predictors. They suggested that PDGF inhibition may be an&#xD;
      option for treatment of NSCLC.&#xD;
&#xD;
      Socinski et al recently described the activity of sunitnib malate (SU11248) an oral,&#xD;
      multitargeted tyrosine kinase inhibitor targeting VEGFR, PDGFR, KIT, FLT3 and RET on tumor&#xD;
      cells, tumor neovasculature and pericytes. In an open-label, two-stage, multicenter phase II&#xD;
      trial evaluating the single-agent activity of sunitinib in refractory NSCLC, patients with&#xD;
      confirmed diagnosis of NSCLC, ECOG PS 0-1, no recent gross hemoptysis, no brain metastases,&#xD;
      patients (pts) previously treated with 1-2 chemotherapy regimens, and adequate end-organ&#xD;
      function, pts received sunitinib at 50 mg/day po for 4 weeks (wks) followed by 2 wks off&#xD;
      treatment (6 wks considered a cycle). A total of 64 pts were enrolled and 63 pts treated. Six&#xD;
      confirmed partial responses have been observed among 63 treated patients. Stable disease has&#xD;
      been observed in an additional 12 pts (19.0% of all treated patients). Based on this study,&#xD;
      Sunitinib appeared to have single-agent activity in previously treated pts with recurrent and&#xD;
      advanced NSCLC, with the level of activity similar to currently approved agents. Sunitinib&#xD;
      was well tolerated in this population. The trial was extended to explore a continuous dosing&#xD;
      strategy of sunitinib at 37.5 mg/day po.&#xD;
&#xD;
      In addition to VEGF and PDGFR, expression of c-kit has been described in NSCLC. Moreover, it&#xD;
      has been found to have an effect on survival. Micke et al, stained the tumor tissue of 95&#xD;
      consecutive patients with adenocarcinoma of the lung, using a polyclonal c-kit antibody.&#xD;
      c-kit expression was correlated with relevant clinical parameters obtained by chart review.&#xD;
      Positive c-kit expression in tumor tissue was observed in 61 of 95 patients (64%). Univariate&#xD;
      analysis showed a significant effect of T (p = 0.003), N (p = 0.001) and M stage (p &lt; 0.001)&#xD;
      as well as of performance status (p = 0.001), surgical resection (p &lt; 0.001), and LDH serum&#xD;
      levels (p = 0.016) on survival. In contrast, c-kit protein expression was non- significant (p&#xD;
      = 0.913). However, multivariate Cox regression with the influential parameters revealed a&#xD;
      significant effect of c-kit expression on survival. They concluded that, the receptor&#xD;
      tyrosine kinase c-kit is frequently expressed in adenocarcinomas of the lung and has a&#xD;
      relevant effect on patient survival. They also concluded that the results of this study&#xD;
      support clinical trials targeting the c-kit receptor with specific c-kit inhibitors.&#xD;
&#xD;
      Combined blockade of VEGF, PDGFR and c-kit may result in better outcomes for patients with&#xD;
      Non Small Cell Lung Carcinoma.&#xD;
&#xD;
      Pazopanib is a novel, orally active small molecule inhibitor targeting multiple tyrosine&#xD;
      kinases including VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-alpha and - beta, and c-kit. An antitumor&#xD;
      effect due to inhibiting of the VEGF driven angiogenic pathway is well established. In&#xD;
      addition to its effects on VEGF receptors, pazopanib targets additional tyrosine kinases&#xD;
      including PDGF receptors and c-kit that have established roles in tumorigenesis and oncogenic&#xD;
      mutations in both have been described. Preliminary data from a phase I study of pazopanib in&#xD;
      patients with solid tumors demonstrated early evidence of antitumor activity. Among 43&#xD;
      patients enrolled, a minimal response occurred in 4 patients and stable disease &gt;6 months,&#xD;
      was observed in an additional 6 patients.&#xD;
&#xD;
      Pazopanib was well tolerated at doses up to 2000 mg daily. Pazopanib is a potent and&#xD;
      selective, orally available, small molecule inhibitor of VEGFR-1, -2, and -3, PDGF-α, PDGF-β,&#xD;
      and c-kit tyrosine kinases (TKs). The agent selectively inhibits proliferation of endothelial&#xD;
      cells stimulated with VEGF but not with basic fibroblast growth factor. In non-clinical&#xD;
      angiogenesis models, pazopanib inhibited VEGF-dependent angiogenesis in a dose-dependent&#xD;
      manner and in xenograft tumor models, twice-daily administration of pazopanib significantly&#xD;
      inhibited tumor growth in mice implanted with various human tumor cells. Upon chronic oral&#xD;
      dosing, pazopanib is expected to inhibit VEGF driven angiogenesis and as a consequence, limit&#xD;
      solid tumor growth. Because angiogenesis is necessary for the growth and metastasis of solid&#xD;
      tumors, and VEGF is believed to have a pivotal role in this process, pazopanib treatment may&#xD;
      have broad-spectrum clinical utility.&#xD;
&#xD;
      Based on its ability to target multiple tyrosine kinases including VEGFR-1, VEGFR-2, VEGFR-3,&#xD;
      PDGFR-alpha and beta and c-kit, which have been implicated in non small cancer, investigation&#xD;
      of Pazopanib in patients with non small cell lung cancer is warranted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was terminated due to positive results seen in statistical analysis. Adequate patient&#xD;
    enrollment was achieved.&#xD;
  </why_stopped>
  <start_date>January 2010</start_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Non Small Cell Lung Cancer Participants With Disease Control (Complete Response+Partial Response+Stable Disease) Based on RECIST 1.0 Measured by CT or MRI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions: Partial Response (PR), &gt;= 30% decrease in the sum of the longest diameter of target lesion, taking as reference the baseline sum of the longest diameter: Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease, taking as reference the smallest sum Longest Diameter since the treatment started</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Describe the Clinical Toxicity Profile of Pazopanib in This Particular Patient Population</measure>
    <time_frame>after the first 6 patients and quarterly</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Pazapanib (GW786034)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib (GW786034)</intervention_name>
    <description>Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months</description>
    <arm_group_label>Pazapanib (GW786034)</arm_group_label>
    <other_name>Pazopanib monohydrochloride salt GW786034</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Required Characteristics 3.1. Subjects must provide written informed consent prior to&#xD;
        performance of study-specific procedures or assessments, and must be willing to comply with&#xD;
        treatment and follow up. Procedures conducted as part of the subject's routine clinical&#xD;
        management (e.g., blood count, imaging study) and obtained prior to signing of informed&#xD;
        consent may be utilized for screening or baseline purposes provided these procedures are&#xD;
        conducted as specified in the protocol.&#xD;
&#xD;
        Note: It is not necessary that informed consent be obtained within the protocol-specified&#xD;
        screening window.&#xD;
&#xD;
        3.11 ≥18 years of age.&#xD;
&#xD;
        3.12 ≥2 prior systemic therapies for Non Small Cell Lung Cancer.&#xD;
&#xD;
        3.13 Histologic or cytologic diagnosis of stage IV Non Small Cell Lung cancer&#xD;
&#xD;
        . 3.14 Measurable disease. For patients having only lesions measuring ≥1 cm to ≤2 cm per&#xD;
        RECIST criteria must use spiral CT imaging for both pre- and post-treatment tumor&#xD;
        assessments.&#xD;
&#xD;
        3.15 Laboratory values obtained ≤14 days prior to registration: Hematologic Absolute&#xD;
        neutrophil count (ANC) 1.5 X 109/L Hemoglobin1 9 g/dL (5.6 mmol/L) Platelets 100 X 109/L&#xD;
        Prothrombin time (PT) or international normalized ratio (INR) 1.2 X upper limit of normal&#xD;
        (ULN) Partial thromboplastin time (PTT) 1.2 X ULN Hepatic2 Total bilirubin 1.5 X ULN AST&#xD;
        and ALT 2.5 X ULN Renal Serum creatinine 1.5 mg/dL (133 µmol/L)&#xD;
&#xD;
        Or, if greater than 1.5 mg/dL:&#xD;
&#xD;
        Calculated creatinine clearance 50 mL/min&#xD;
&#xD;
        Urine Protein to Creatinine Ratio (UPC)3 &lt; 1&#xD;
&#xD;
          1. Subjects may not have had a transfusion within 7 days of screening assessment.&#xD;
&#xD;
          2. Concomitant elevations in bilirubin and AST/ALT above 1.0 x ULN are not permitted&#xD;
&#xD;
          3. If UPC &gt;/= 1, then a 24-hour urine protein must be assessed. Subjects must have a&#xD;
             24-hour urine protein value &lt;1g to be eligible.&#xD;
&#xD;
             3.16 ECOG Performance Score 0, or 1.&#xD;
&#xD;
             3.17 Negative pregnancy test done ≤ 7 days prior to registration, for women of&#xD;
             childbearing potential only.&#xD;
&#xD;
             A female is eligible to enter and participate in this study if she is of:&#xD;
             Non-childbearing potential (i.e., physiologically incapable of becoming pregnant),&#xD;
             including any female who has had:&#xD;
&#xD;
               -  A hysterectomy&#xD;
&#xD;
               -  A bilateral oophorectomy (ovariectomy)&#xD;
&#xD;
               -  A bilateral tubal ligation&#xD;
&#xD;
               -  Is post-menopausal&#xD;
&#xD;
             Subjects not using hormone replacement therapy (HRT) must have experienced total&#xD;
             cessation of menses for ≥ 1 year and be greater than 45 years in age, OR, in&#xD;
             questionable cases, have a follicle stimulating hormone (FSH) value &gt;40 mIU/mL and an&#xD;
             estradiol value &lt; 40pg/mL (&lt;140 pmol/L).&#xD;
&#xD;
             Subjects using HRT must have experienced total cessation of menses for &gt;= 1 year and&#xD;
             be greater than 45 years of age OR have had documented evidence of menopause based on&#xD;
             FSH and estradiol concentrations prior to initiation of HRT&#xD;
&#xD;
             Childbearing potential, including any female who has had a negative serum pregnancy&#xD;
             test within 1 week prior to the first dose of study treatment, preferably as close to&#xD;
             the first dose as possible, and agrees to use adequate contraception. GSK acceptable&#xD;
             contraceptive methods, when used consistently and in accordance with both the product&#xD;
             label and the instructions of the physician, are as follow:&#xD;
&#xD;
               -  An intrauterine device with a documented failure rate of less than 1% per year.&#xD;
&#xD;
               -  Vasectomized partner who is sterile prior to the female subject's entry and is&#xD;
                  the sole sexual partner for that female.&#xD;
&#xD;
               -  Complete abstinence from sexual intercourse for 14 days before exposure to&#xD;
                  investigational product, through the dosing period, and for at least 21 days&#xD;
                  after the last dose of investigational product.&#xD;
&#xD;
               -  Double-barrier contraception (condom with spermicidal jelly, foam suppository, or&#xD;
                  film; diaphragm with spermicide; or male condom and diaphragm with spermicide).&#xD;
&#xD;
               -  Oral contraceptives&#xD;
&#xD;
               -  Female subjects who are lactating should discontinue nursing prior to the first&#xD;
                  dose of study drug and should refrain from nursing throughout the treatment&#xD;
                  period and for 14 days following the last dose of study drug&#xD;
&#xD;
             3.18 Ability and willingness to provide informed consent.&#xD;
&#xD;
             3.19 Life expectancy ≥12 weeks.&#xD;
&#xD;
             -&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
             3.21 Any of the following as this regimen may be harmful to a developing fetus or&#xD;
             nursing child.&#xD;
&#xD;
             • Pregnant women&#xD;
&#xD;
               -  Nursing women&#xD;
&#xD;
               -  Men or women of childbearing potential or their sexual partners who are unwilling&#xD;
                  to employ adequate contraception.&#xD;
&#xD;
             3.22 Any abnormal serum calcium, magnesium, and potassium levels&#xD;
&#xD;
             3.23 Clinically significant hemoptysis, cerebral hemorrhage, or gastrointestinal&#xD;
             hemorrhage in the past 6 months&#xD;
&#xD;
             3.24 Any patient currently on an antiarrhythmics or other medications that are know to&#xD;
             prolong the QT interval.&#xD;
&#xD;
             3.25 Uncontrolled infection.&#xD;
&#xD;
             3.26 Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥140&#xD;
             mmHg or diastolic blood pressure (DBP) of ≥ 90mmHg].&#xD;
&#xD;
             Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to&#xD;
             study entry. BP must be re-assessed on two occasions that are separated by a minimum&#xD;
             of 1 hour; on each of these occasions, the mean (of 3 readings) SBP / DBP values from&#xD;
             each BP assessment must be &lt;140/90 mmHg in order for a subject to be eligible for the&#xD;
             study&#xD;
&#xD;
             3.27 Any condition (e.g., gastrointestinal tract disease resulting in an inability to&#xD;
             take oral medication or a requirement for IV alimentation, prior surgical procedures,&#xD;
             affecting absorption, or active peptic ulcer disease) that impairs their ability to&#xD;
             swallow and retain pazopanib tablets.&#xD;
&#xD;
               -  Malabsorption syndrome&#xD;
&#xD;
               -  Major resection of the stomach or small bowel. 3.28 Clinically significant&#xD;
                  gastrointestinal abnormalities that may increase the risk for gastrointestinal&#xD;
                  bleeding including, but not limited to:&#xD;
&#xD;
               -  Active peptic ulcer disease&#xD;
&#xD;
               -  Known intraluminal metastatic lesion/s with risk of bleeding&#xD;
&#xD;
               -  Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other&#xD;
                  gastrointestinal conditions with increased risk of perforation&#xD;
&#xD;
               -  History of abdominal fistula, gastrointestinal perforation, or intra abdominal&#xD;
                  abscess within 28 days prior to beginning study treatment.&#xD;
&#xD;
             3.29 Known endobronchial lesions and or lesions infiltrating major pulmonary vessels.&#xD;
&#xD;
             3.30 Cavitary lesions deemed to be at increased risk of bleeding.&#xD;
&#xD;
             3.31 Any other severe underlying diseases that are, in the judgment of the&#xD;
             investigator, inappropriate for entry into this study.&#xD;
&#xD;
             3.32 Second primary malignancy except for carcinoma in situ of the cervix or&#xD;
             nonmelanomatous skin cancer, unless that prior malignancy was diagnosed and&#xD;
             definitively treated ≥5 years previously with no subsequent evidence of recurrence.&#xD;
             Patients with a history of low-grade (Gleason score ≤6) localized prostate cancer will&#xD;
             be eligible even if diagnosed &lt;5 years prior to registration.&#xD;
&#xD;
             3.33 Any ancillary therapy considered investigational (utilized for a non-FDA approved&#xD;
             indication and in the context of a research investigation) ≤4 weeks prior to&#xD;
             registration.&#xD;
&#xD;
             3.34 Other concurrent chemotherapy, immunotherapy, radiotherapy.&#xD;
&#xD;
             3.35a. History of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to pazopanib or other agents used in the study.&#xD;
&#xD;
             b. Medications that act through the CYP450 system. Some medications that act through&#xD;
             the cytochrome P450 system are specifically prohibited in patients receiving&#xD;
             pazopanib. Certain other agents should be used with caution. (A list of medications&#xD;
             that are specifically prohibited or that should be used with caution during this trial&#xD;
             of pazopanib will be provided with the full study protocol as Appendix 1. A list of&#xD;
             selected agents that could affect pazopanib will be listed in Appendix I. ) c. Any of&#xD;
             the following concurrent severe and/or uncontrolled medical conditions:&#xD;
&#xD;
             • Serious or non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
             • History of abdominal fistula, diverticulosis, gastrointestinal perforation, or&#xD;
             intra-abdominal abscess ≤28 days prior to registration&#xD;
&#xD;
               -  Any history of cerebrovascular accident (CVA) ≤6 months prior to registration&#xD;
&#xD;
               -  History of any one or more of the following cardiovascular conditions within the&#xD;
                  past 6 months:&#xD;
&#xD;
               -  Cardiac angioplasty or stenting&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Coronary artery bypass graft surgery&#xD;
&#xD;
               -  Symptomatic peripheral vascular disease&#xD;
&#xD;
               -  Class III or IV congestive heart failure, as defined by the New York Heart&#xD;
                  Association (NYHA)&#xD;
&#xD;
               -  History of venous thrombosis ≤12 weeks prior to registration.&#xD;
&#xD;
               -  Class III or IV heart failure as defined by the NYHA functional classification&#xD;
                  system .History of Class II heart failure and is asymptomatic on treatment may be&#xD;
                  considered eligible.&#xD;
&#xD;
               -  Poorly controlled diabetes.&#xD;
&#xD;
               -  Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the&#xD;
                  lung.&#xD;
&#xD;
               -  QTc prolongation (defined as a QTc interval ) &gt; 480 msecs using Bazett's formula)&#xD;
                  or other significant ECG abnormalities d. Symptomatic, untreated, or uncontrolled&#xD;
                  CNS metastases or seizure disorder. Patients with CNS metastases treated with&#xD;
                  whole brain radiation (WBRT)or gamma knife may be enrolled after completion of&#xD;
                  WBRT or gamma knife. Patients may begin chemotherapy as early as the next day&#xD;
                  after completion of WBRT or gamma knife.&#xD;
&#xD;
                  e. Uncontrolled intercurrent illness including, but not limited to, ongoing or&#xD;
                  active infection or psychiatric illness/social situations that would limit&#xD;
                  compliance with study requirements.&#xD;
&#xD;
                  f. HIV-positive patients on combination antiretroviral therapy because of the&#xD;
                  potential for pharmacokinetic interactions with pazopanib. In addition, these&#xD;
                  patients are at increased risk of lethal infections when treated with marrow&#xD;
                  suppressive therapy&#xD;
&#xD;
                  g. Any of the following prior therapies:&#xD;
&#xD;
               -  Major surgery (i.e., laparotomy), open biopsy, or significant traumatic injury ≤4&#xD;
                  weeks prior to registration. Minor surgery ≤4 weeks prior to registration.&#xD;
                  Insertion of a vascular access device is not considered major or minor surgery in&#xD;
                  this regard.&#xD;
&#xD;
               -  Treatment with any of the following anti-cancer therapies:&#xD;
&#xD;
               -  radiation therapy, surgery or tumor embolization within 14 days prior to the&#xD;
                  first dose of Pazopanib OR&#xD;
&#xD;
               -  chemotherapy, immunotherapy, biologic therapy, investigational therapy or&#xD;
                  hormonal therapy within 14 days or five half-lives of a drug (whichever is&#xD;
                  longer) prior to the first dose of pazopanib&#xD;
&#xD;
             Patients with progressive disease inside of the radiation field are not eligible.&#xD;
&#xD;
             3.36 History of cerebrovascular accident including transient ischemic attack (TIA),&#xD;
             pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.&#xD;
&#xD;
             Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating&#xD;
             agents for at least 6 weeks are eligible&#xD;
&#xD;
             3.37 Evidence of active bleeding or bleeding diathesis.&#xD;
&#xD;
             3.38 Hemoptysis within 6 weeks of first dose of study drug.&#xD;
&#xD;
             3.39 Unable or unwilling to discontinue use of prohibited medications for at least 14&#xD;
             days or five half-lives of a drug (whichever is longer) prior to the first dose of&#xD;
             study drug and for the duration of the study.&#xD;
&#xD;
             3.40 Any ongoing toxicity from prior anti-cancer therapy that is &gt;Grade 1 and/or that&#xD;
             is progressing in severity, except alopecia.&#xD;
&#xD;
             3.41 Other Eligibility Criteria Considerations To assess any potential impact on&#xD;
             subject eligibility with regard to safety, the investigator must refer to the&#xD;
             following document(s) for detailed information regarding warnings, precautions,&#xD;
             contraindications, adverse events, and other significant data pertaining to the&#xD;
             investigational product(s) being used in this study: Clinical Investigator's Brochure&#xD;
             for pazopanib.[Investigator Brochure]&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sachdev P. Thomas, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Illinois CancerCare, P.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Canton</city>
        <state>Illinois</state>
        <zip>61520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Carthage</city>
        <state>Illinois</state>
        <zip>62321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Eureka</city>
        <state>Illinois</state>
        <zip>61530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Macomb</city>
        <state>Illinois</state>
        <zip>61455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Monmouth</city>
        <state>Illinois</state>
        <zip>61462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Ottawa</city>
        <state>Illinois</state>
        <zip>61350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Pekin</city>
        <state>Illinois</state>
        <zip>61554</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Peru</city>
        <state>Illinois</state>
        <zip>61354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Princeton</city>
        <state>Illinois</state>
        <zip>61356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <results_first_submitted>August 11, 2014</results_first_submitted>
  <results_first_submitted_qc>September 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 19, 2014</results_first_posted>
  <last_update_submitted>September 16, 2014</last_update_submitted>
  <last_update_submitted_qc>September 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Illinois CancerCare, P.C.</investigator_affiliation>
    <investigator_full_name>Sachdev Thomas</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lung Cancer Non Small Cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pazapanib (GW786034)</title>
          <description>Pazopanib (GW786034): Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Stratification was performed based on histology of disease. Enrollment was targeted to 21 patients with squamous histology and 21 patients with non- squamous histology. Due to the lack of patients with squamous histology, the study was closed prior to meeting the enrollment goal of 44 subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>Pazapanib (GW786034)</title>
          <description>Pazopanib (GW786034): Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Non Small Cell Lung Cancer Participants With Disease Control (Complete Response+Partial Response+Stable Disease) Based on RECIST 1.0 Measured by CT or MRI</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions: Partial Response (PR), &gt;= 30% decrease in the sum of the longest diameter of target lesion, taking as reference the baseline sum of the longest diameter: Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease, taking as reference the smallest sum Longest Diameter since the treatment started</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pazapanib (GW786034)</title>
            <description>Pazopanib (GW786034): Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Non Small Cell Lung Cancer Participants With Disease Control (Complete Response+Partial Response+Stable Disease) Based on RECIST 1.0 Measured by CT or MRI</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions: Partial Response (PR), &gt;= 30% decrease in the sum of the longest diameter of target lesion, taking as reference the baseline sum of the longest diameter: Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease, taking as reference the smallest sum Longest Diameter since the treatment started</description>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" lower_limit="0.21" upper_limit="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Describe the Clinical Toxicity Profile of Pazopanib in This Particular Patient Population</title>
        <time_frame>after the first 6 patients and quarterly</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pazapanib (GW786034)</title>
          <description>Pazopanib (GW786034): Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <description>lymphopenia</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders - Other, specify</sub_title>
                <description>nonspecific T-wave abnormality</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/Bone Marrow- AML</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>INR</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>PTT</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Edema: Limb</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Albumin, serum- low</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>ALT (SGPT)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>AST (SGOT)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Calcium, serum- high</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Calcium, serum- low</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Glomerular Filtration Rate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Glucose, serum- high</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Glucose, serum- low</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Magnesium, serum- high</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Magnesium, serum- low</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Phosphate, serum- low</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Potassium, serum- high</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Potassium, serum- low</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Sodium, serum- high</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Sodium, serum- low</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Triglyceride, serum- high</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Bicarbonate, serum low</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrythmia- Systolic Anterior Motion</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cardiac Troponin I</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Left Ventricular Systolic Dysfunction (LVSD)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Mitral Regurgitation</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Prolonged QTc Interval</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Supraventricular and Nodal Arrhthymia- Atrial Fibrillation</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Supraventricular and Nodal Arrhthymia- Sinus Bradycardia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Supraventricular and Nodal Arrhthymia- Sinus Tachycardi</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Ventricular Arrythmia- PVCs</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes/Flushes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Thyroid Function, low</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Thyroid Function, high</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision- Blurred Vision</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vision- Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vision- Flashing Lights/Floaters</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Watery Eyes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dry Mouth/Salivary Gland</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Heartburn/Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Taste Alteration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Distention/Bloating- Abdominal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI- Lower GI NOS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rigors/Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GU- Urinary NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Pulmonary/Upper Respiratory- Nose</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Abdomen</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Back</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Bone</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Chest</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- External Ear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Extremity, Limb</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Finger</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Joint</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Muscle</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Neck</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- General NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Shoulder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Syndromes- Systemic Inflammatory Response System (SIRS)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver Dysfunction/Failure</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Blood</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Lung (Pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Respiratory Tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Sinus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Stomach</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Thrush</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Upper Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Urinary Tract</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Upper Airway NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Oral Cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Rhinitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Muscle Weakness- generalized</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Muscle Weakness- upper extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue- Leg Cramps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue- Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue- Plantar Fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Laryngeal Nerve Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Mood Alteration- Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Neurology- Tremors</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Neuropathy: Motor</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Neuropathy: Sensory</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Syncope (Fainting)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Mood Alteration- Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Somnolence/Depressed Level of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Incontinence, Urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Urinary Frequency/Urgency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, Pulmonary/Upper Respiratory- Respiratory Tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Bronchospasm/Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Voice Changes/Dysathria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hiccoughs (Hiccups/Singultus)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pneumonitis/Pulmonary Infiltrates</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypopigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nail Changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the lack of patients with squamous histology, the study was closed prior to meeting the enrollment goal of 44 subjects.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sachdev Thomas, M.D.</name_or_title>
      <organization>Illinois CancerCare, P.C.</organization>
      <phone>309-243-3000</phone>
      <email>sthomas@illinoiscancercare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

